MedTrace Logo

A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis

NCT07533955 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-04-21

No results posted yet for this study

Summary

This is a Phase 1, first in human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE201 compared to placebo in participants with Rheumatoid Arthritis

Conditions

  • Rhematoid Arthritis

Interventions

DRUG

JADE201

JADE201 is supplied as sterile solution to be administered by SC injection.

DRUG

Placebo

Placebo solution to be administered at a matching volume by SC injection.

Sponsors & Collaborators

  • Jade Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-10-31
Completion
2028-10-31

Countries

  • Moldova
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07533955 on ClinicalTrials.gov